Currently Viewing:
The American Journal of Managed Care June 2019
Currently Reading
Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated
Bruce Feinberg, DO; Jonathan Kish, PhD, MPH; Igoni Dokubo, MD; Jeff Wojtynek, PharmD; and Kevin Lord, PhD, MHS
Association of Decision Support for Hospital Discharge Disposition With Outcomes
Winthrop F. Whitcomb, MD; Joseph E. Lucas, PhD; Rachel Tornheim, MBA; Jennifer L. Chiu, MPH; and Peter Hayward, PhD
US Care Pathways: Continued Focus on Oncology and Outstanding Challenges
Anita Chawla, PhD; Kimberly Westrich, MA; Angela Dai, BS, BA; Sarah Mantels, MA; and Robert W. Dubois, MD, PhD
Understanding Price Growth in the Market for Targeted Oncology Therapies
Jesse Sussell, PhD; Jacqueline Vanderpuye-Orgle, PhD; Diana Vania, MSc; Hans-Peter Goertz, MPH; and Darius Lakdawalla, PhD
Cancer Care Spending and Use by Site of Provider-Administered Chemotherapy in Medicare
Andrew Shooshtari, BS; Yamini Kalidindi, MHA; and Jeah Jung, PhD
Will 2019 Kick Off a New Era in Person-Centered Care?
Ann Hwang, MD; and Marc A. Cohen, PhD
Enhanced Care Coordination Improves HIV Viral Load Suppression Rates
Ross G. Hewitt, MD; Debra Williams, EdD; Richard Adule; Ira Feldman, MPS; and Moe Alsumidaie, MBA, MSF
Impact of Care Coordination Based on Insurance and Zip Code
Jennifer N. Goldstein, MD, MSc; Merwah Shinwari, BS; Paul Kolm, PhD; Daniel J. Elliott, MD, MSCE; William S. Weintraub, MD; and LeRoi S. Hicks, MD, MPH
Changing Electronic Formats Is Associated With Changes in Number of Laboratory Tests Ordered
Gari Blumberg, MD; Eliezer Kitai, MD; Shlomo Vinker, MD; and Avivit Golan-Cohen, MD
Health Insurance Design and Conservative Therapy for Low Back Pain
Kathleen Carey, PhD; Omid Ameli, MD, MPH; Brigid Garrity, MS, MPH; James Rothendler, MD; Howard Cabral, PhD; Christine McDonough, PhD; Michael Stein, MD; Robert Saper, MD, MPH; and Lewis Kazis, ScD
Improving Quality Measure Maintenance: Navigating the Complexities of Evolving Evidence
Thomas B. Valuck, MD, JD; Sarah Sampsel, MPH; David M. Sloan, PhD; and Jennifer Van Meter, PharmD

Reports of the Demise of Chemotherapy Have Been Greatly Exaggerated

Bruce Feinberg, DO; Jonathan Kish, PhD, MPH; Igoni Dokubo, MD; Jeff Wojtynek, PharmD; and Kevin Lord, PhD, MHS
The expanding arsenal of targeted and immuno-oncology drugs has unalterably changed the landscape of systemic cancer treatment, but chemotherapy will remain critical for years if not decades to come.
ABSTRACT

Does the rapid integration of both targeted and immuno-oncology drugs into treatment guidelines across solid tumors and hematologic malignancies herald the beginning of the end of chemotherapy as a foundational element in systemic cancer treatment? We respond to similar assertions posited after the 2018 American Society of Clinical Oncology Annual Meeting with an analysis of past, current, and future treatment of breast cancer—a tumor central to the evolution of modern cancer treatment principles. Our conclusions assert that reports of the demise of chemotherapy are greatly exaggerated and, as chemotherapy is likely to remain foundational for years to come, research is warranted to improve its patient-centricity.

Am J Manag Care. 2019;25(6):270-272
Takeaway Points
  • Scientific achievements and regulatory enhancements have resulted in a dramatic increase in targeted and immunologic cancer drug approvals.
  • The resulting change in clinical guidelines has caused some to posit a chemotherapy-free future for cancer treatment.
  • The realities of disease natural history, current practice, and ongoing clinical trials suggest that such a future is much further off.
  • As long as chemotherapy remains critical to cancer treatment, additional research is needed to increase its patient-centricity.
The listserv headlines accompanying the opening of the 2018 American Society of Clinical Oncology Annual Meeting were intended to be provocative. Medscape ran the headline “ ‘End of an Era’ for Chemo in Non-Small Cell Lung Cancer” on June 3, 2018.1 The reality was more nuanced, as the research suggested that those patients with advanced non–small cell lung cancer (aNSCLC) whose tumors expressed progressive death ligand-1 might avoid having chemotherapy as a first-line treatment.2 But the point wasn’t to be nuanced; rather, it was intentional—a shot across the bow to herald the beginning of a new era in cancer medicine, one in which chemotherapy was no longer the backbone of systemic treatment. An expanding arsenal of targeted and immunologic therapies was not only resulting in chemotherapy-free treatment guidelines for rarer cancers like renal cell carcinoma and melanoma but was also transforming the treatment of the most common and lethal of cancers. The declaration was met with giddy optimism, teasing the reader with the notion that chemotherapy may soon become a footnote in cancer treatment history alongside Coley’s toxin and cobalt. What did the emergence of targeted therapies, checkpoint inhibitors, chimeric antigen receptor T-cell therapy, vaccines, and novel gene therapies mean for systemic cytotoxic drugs as the backbone of solid tumor, lymphoma, and much of leukemia management? A review of the past, current, and near future of the systemic treatment of breast cancer (BC)—the archetype of cytotoxic therapy development—might shed light on the continued role of chemotherapy in the management of advanced cancer in both the near and long term.

The Origins of Systemic Chemotherapy Treatment of BC

The innovation of targeted and immunologic therapies and the resulting rapidly evolving treatment paradigms we witness today very much mirror the sequential advancement of chemotherapy 60 years ago. Following the introduction of 5-fluorouracil (5-FU) in the late 1950s, considerable advances in the understanding of cancer carcinogenesis, cell cycle kinetics, and mutational targets led to numerous paradigm shifts in the systemic treatment of advanced malignancies.3 After an initial surge of drug approvals with differing mechanisms of action, research shifted to combination chemotherapy in the hopes of increased efficacy with less dose-limiting toxicity.3-5 At the forefront of this research was investigation into BC treatments, beginning with the combination of cyclophosphamide, methotrexate, and 5-FU in the 1970s, followed by anthracycline-based regimens in the 1980s and taxane-based combinations in the 1990s.3,6 This golden age of chemotherapy discovery appeared to sunset as explorations of dose density and dose intensification, supported by bone marrow (stem cell) transplant, ended the decade with one of the darker chapters in BC research.

The New Millennium

Although progress continued in the development of new chemotherapeutic agents for the salvage treatment of metastatic BC (mBC) (capecitabine, 1998; nab-paclitaxel, 2005; ixabepilone, 2007; eribulin, 2010), researchers at the start of the new millennium seemed more focused on limiting chemotherapy toxicity via improved supportive care while reducing chemotherapy exposure via genetic profiling.7,8 Clinical trials testing hormonal and human epidermal growth factor receptor 2 therapies dominated meeting presentations. More recently, novel therapeutics including cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors, poly (ADP-ribose) polymerase inhibitors, and checkpoint inhibitors have gained FDA approval, thus rapidly altering treatment guidelines and establishing new standards of care for first-line treatment of mBC. The latest additions to this arsenal—likely to continue this trend—are the phosphoinositide 3-kinase inhibitors. The rapid expansion of the mBC systemic, nonchemotherapy cancer arsenal would appear to support the contention that, like in aNSCLC, the need for conventional chemotherapy in mBC is fading. However, critical differences in the mBC patient journey challenge that prediction.

An Exaggerated Report of Death

There are stark differences in the epidemiology of BC versus aNSCLC. First, unlike aNSCLC, in which the majority of patients are initially diagnosed with advanced disease, more than 85% of patients with BC present with lower-stage disease, with many receiving adjuvant chemotherapy.6 Given the longer clinical trial time required for proof of superiority in the adjuvant setting, it is unlikely that chemotherapy will be displaced from adjuvant BC treatment in the foreseeable future. Second, overall median survival from diagnosis of mBC is much longer than that of aNSCLC (approximately 24 months and 10 months, respectively), with patients exposed to many more lines of systemic therapy.7-11 Real-world studies have shown that an increasing number of patients with mBC receive more than 5 lines of therapy.6 In a retrospective analysis, the proportions of patients with BC receiving fifth, sixth, and seventh or greater lines of therapy in 2007 were 15.8%, 8.2%, and 5.1%, respectively, which increased to 28.2%, 18.7%, and 12.3% in 2010.6 These patients derived a clinical benefit, with each subsequent line extending their overall survival by 8.7, 8.2, and 7.5 months in the fifth, sixth, and seventh lines of therapy, respectively.6 The fact that chemotherapy is foundational to the neoadjuvant, adjuvant, and metastatic treatment of BC, as well as its use in combination with targeted and immuno-oncology approved drugs, would suggest that current and future patients with BC will be receiving multiple lines of systemic chemotherapy for many years to come. However, could the scientific and regulatory processes that have expedited the changes in the guideline treatment of aNSCLC alter the chemotherapy paradigm much sooner than history would predict?


 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up